the latest coin Related searches

Shanghai Electric established a new company including machinery and equipment sales business. According to the enterprise search APP, Shanghai Dixi New Energy Co., Ltd. was established with Ye Can as its legal representative and registered capital of 1 million yuan. Its business scope includes: power generation business, power transmission business and power supply (distribution) business; Installation, maintenance and testing of power transmission, power supply and power reception facilities; Mechanical equipment sales; Mechanical and electrical equipment sales, etc. Enterprise survey shows that the company is wholly owned by Shanghai Electric New Energy Development Co., Ltd., a subsidiary of Shanghai Electric.Barclays: The Central Economic Work Conference released more signals of policy support, which was held in Beijing from December 11th to 12th. The Barclays research team said that the Central Economic Work Conference provided more forward-looking guidance and released more policy support signals. Barclays said that on the whole, the meeting made it clear that "stable economic growth should be maintained next year" and emphasized "implementing more active macro policies" and "vigorously boosting consumption". The agency believes that regulators are more likely to introduce policies in a gradual manner. At the same time, when measuring the rhythm, scale and composition of the next round of measures, we should focus on the development and changes of real estate and stock market. Barclays expects that a more specific financial plan will be announced in March next year. In terms of monetary policy, the meeting proposed to implement a "moderately loose monetary policy". Barclays believes that this change in wording and position has released a positive signal, especially considering the current environment, it is expected that the central bank may cut interest rates significantly in the future. (SSE)Mitsubishi electric will invest $143.5 million to build a heat pump factory in the United States.

On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Anhui procuratorate prosecuted Huawei Yu, the former deputy general manager of Anhui Investment Group Holding Co., Ltd., for allegedly accepting bribes. According to the highest inspection news, a few days ago, Huawei Yu, the former party member and deputy general manager of Anhui Investment Group Holding Co., Ltd., was suspected of accepting bribes, and the Huainan Municipal People's Procuratorate filed a public prosecution with the Huainan Intermediate People's Court according to law after the jurisdiction designated by the Anhui Provincial People's Procuratorate. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Huawei Yu of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. The People's Procuratorate of Huainan City charged that the defendant Huawei Yu, as a national staff member, used the convenience of his position and the convenience of his authority or position to seek benefits for others through the actions of other national staff members, and illegally accepted other people's property alone or in collusion with others. The amount was extremely huge, so he should be investigated for criminal responsibility for accepting bribes according to law.

Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)It is predicted that the State Council Press Office will hold a press conference at 10 am on Monday, December 16th, 2024, and ask Fu Linghui, spokesperson of the National Bureau of Statistics and head of the National Economic Statistics Department, to introduce the national economic operation in November 2024 and answer questions from reporters.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.